Literature DB >> 15585447

Carisoprodol withdrawal syndrome.

Roy R Reeves1, John J Beddingfield, James E Mack.   

Abstract

A 43-year-old man with chronic back and shoulder pain was treated with hydrocodone. He began taking excessive amounts of the drug, so his physicians stopped prescribing it. The patient then obtained the muscle relaxant carisoprodol on his own from several sources. He was consuming up to 30 or more tablets/day (> or =10,500 mg/day) for several weeks, then abruptly stopped taking the drug. Within 48 hours he developed anxiety, tremors, muscle twitching, insomnia, auditory and visual hallucinations, and bizarre behavior. The symptoms intensified and peaked on the fourth day after carisoprodol cessation. The patient required brief treatment with olanzapine and tapering dosages of lorazepam while the symptoms gradually resolved. To our knowledge, this is the first documented case of a withdrawal syndrome with carisoprodol. The symptoms most likely resulted because of accumulation of meprobamate, the active metabolite of carisoprodol in humans. Clinicians prescribing carisoprodol should be aware of the possibility for abuse or addiction. Further, we recommend that carisoprodol be designated a controlled substance at the federal level.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585447     DOI: 10.1592/phco.24.17.1804.52333

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  7 in total

1.  Carisoprodol pharmacokinetics and distribution in the nucleus accumbens correlates with behavioral effects in rats independent from its metabolism to meprobamate.

Authors:  Theresa M Carbonaro; Vien Nguyen; Michael J Forster; Michael B Gatch; Laszlo Prokai
Journal:  Neuropharmacology       Date:  2020-05-29       Impact factor: 5.250

2.  Carisoprodol tolerance and precipitated withdrawal.

Authors:  Michael B Gatch; Jacques D Nguyen; Theresa Carbonaro; Michael J Forster
Journal:  Drug Alcohol Depend       Date:  2011-11-04       Impact factor: 4.492

3.  Carisoprodol use and abuse in Norway: a pharmacoepidemiological study.

Authors:  Jørgen G Bramness; Kari Furu; Anders Engeland; Svetlana Skurtveit
Journal:  Br J Clin Pharmacol       Date:  2007-02-12       Impact factor: 4.335

4.  Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma.

Authors:  Gunchan Paul; Gautam L Parshotam; Rajneesh Garg
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Jul-Sep

5.  Single and Multiple Dose PK-PD Characterization for Carisoprodol. Part I: Pharmacokinetics, Metabolites, and 2C19 Phenotype Influence. Double-Blind, Placebo-Controlled Clinical Trial in Healthy Volunteers.

Authors:  Aitana Calvo; Saioa Alonso; Esther Prieto; Ana Ascaso-Del-Rio; Jordi Ortuño; Nieves Fernandez; Antonio Portolés
Journal:  J Clin Med       Date:  2022-02-06       Impact factor: 4.241

6.  Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers.

Authors:  Aitana Calvo; Mercedes González-Hidalgo; Ana Terleira; Nieves Fernández; Antonio Portolés
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241

7.  Carisoprodol withdrawal induced delirium: A case study.

Authors:  Karen Ni; Margaret Cary; Paul Zarkowski
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.